NASDAQ · SCLXW
Healthcare · Drug Manufacturers - General
$0.07
Down-$0.00 (-5.45%)
Updated Oct 10, 2026, 4:25 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SCLXW
1M range · 13 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
SCLXW closed at $0.07 after 13 trading sessions, down 34.09% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $0.0725 | $0.0725 | $0.0725 | $0.0725 | 5.27K |
| Oct 8, 2026 | $0.0899 | $0.09 | $0.0899 | $0.0899 | 1.38K |
| Oct 2, 2026 | $0.06 | $0.10 | $0.06 | $0.10 | 2.1K |
| Sep 30, 2026 | $0.10 | $0.10 | $0.0999 | $0.0999 | 10.11K |
| Sep 29, 2026 | $0.0684 | $0.0901 | $0.0684 | $0.0901 | 1.59K |
| Sep 25, 2026 | $0.08 | $0.0927 | $0.08 | $0.088 | 6.72K |
| Sep 22, 2026 | $0.0627 | $0.0627 | $0.0627 | $0.0627 | 230 |
| Sep 21, 2026 | $0.09 | $0.09 | $0.09 | $0.09 | 284 |
| Sep 18, 2026 | $0.0998 | $0.10 | $0.0912 | $0.10 | 13.9K |
| Sep 17, 2026 | $0.0825 | $0.11 | $0.0825 | $0.0851 | 2.93K |
| Sep 16, 2026 | $0.1187 | $0.1187 | $0.1187 | $0.1187 | 920 |
| Sep 15, 2026 | $0.09 | $0.09 | $0.0899 | $0.0899 | 375 |
| Sep 11, 2026 | $0.06 | $0.11 | $0.06 | $0.11 | 7.65K |
The latest Smart Investors Daily articles mentioning SCLXW.
Company
Market Activity
Research & News
SCLXW research
Company profile and research snapshot.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Jul 6, 2026
Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SCLXW.
No results
No recent SID articles mention SCLXW.
